drugset / Trial / NCT00492843

Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

NCT00492843

Phase 4 Terminated 20 enrolled Chinese Society of Lung Cancer
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this trial is to assess the efficacy and safety of loading doses versus standard dose of intravenous Bondronat in reducing pain in patients with lung cancer and bone metastatic disease.

Timeline

Start
2007-07
Primary completion
2008-01
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibandronate Other / unclassified 6 mg Intravenous

Indications